SGLT2 inhibitors vs placebo: Death (all causes)
- Population
- people with diabetes and CKD
- Intervention
- SGLT2 inhibitors
- Comparison
- placebo
- Outcome
- Death (all causes)
Reviews word the same question differently. Two decision models (TypeSafe's Jev and Liquid AI's d1) judged each wording of the population, intervention, comparator and outcome against the others, and rows count as this question only when both agree on all four. Timing, setting and subgroup never split a question: they are shown on each row.
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
How each review answered it
Current versions only| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors vs placebo All‐cause death median · people with CKD and diabetes Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes (2024) · Cochrane | RR 0.86 [0.81, 0.92] | 20 studies · 44397 participants | High |
SGLT2 inhibitors vs placebo Death (all causes) · people with diabetes and CKD Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease (2018) · Cochrane | no estimate extracted | 5 studies · 2933 participants | Very low |
Trials and studies behind the answers
The primary studies that full-text reviews tie to these outcomes. Reviews from the Summary of Findings tier list no included studies here, and trials have not yet been matched to questions on their own, so this list is incomplete.